- Home
- SHIP vs CHRS Comparison
SHIP vs CHRS Comparison
Compare SHIP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHIP
- CHRS
- Stock Information
- Founded
- SHIP 2008
- CHRS 2010
- Country
- SHIP Greece
- CHRS United States
- Employees
- SHIP N/A
- CHRS N/A
- Industry
- SHIP Marine Transportation
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SHIP Consumer Discretionary
- CHRS Health Care
- Exchange
- SHIP Nasdaq
- CHRS Nasdaq
- Market Cap
- SHIP 131.9M
- CHRS 112.5M
- IPO Year
- SHIP 2007
- CHRS 2014
- Fundamental
- Price
- SHIP $6.57
- CHRS $0.76
- Analyst Decision
- SHIP Strong Buy
- CHRS Buy
- Analyst Count
- SHIP 1
- CHRS 3
- Target Price
- SHIP $11.00
- CHRS $4.68
- AVG Volume (30 Days)
- SHIP 121.3K
- CHRS 1.2M
- Earning Date
- SHIP 08-05-2025
- CHRS 08-07-2025
- Dividend Yield
- SHIP 9.92%
- CHRS N/A
- EPS Growth
- SHIP 48.17
- CHRS N/A
- EPS
- SHIP 1.26
- CHRS N/A
- Revenue
- SHIP $153,372,000.00
- CHRS $272,251,000.00
- Revenue This Year
- SHIP N/A
- CHRS N/A
- Revenue Next Year
- SHIP $21.78
- CHRS $132.69
- P/E Ratio
- SHIP $5.35
- CHRS N/A
- Revenue Growth
- SHIP 17.53
- CHRS 19.87
- 52 Week Low
- SHIP $4.78
- CHRS $0.66
- 52 Week High
- SHIP $12.65
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- SHIP 55.40
- CHRS 40.60
- Support Level
- SHIP $6.70
- CHRS $0.74
- Resistance Level
- SHIP $7.01
- CHRS $0.79
- Average True Range (ATR)
- SHIP 0.23
- CHRS 0.05
- MACD
- SHIP 0.00
- CHRS 0.00
- Stochastic Oscillator
- SHIP 48.84
- CHRS 12.76
About SHIP Seanergy Maritime Holdings Corp.
Seanergy Maritime Holdings Corp is an international shipping company that provides marine dry bulk transportation services through the ownership and operation of dry bulk vessels. It generates a majority of its revenue from the vessels. The company's fleet of vessels includes Fellowship, Championship, Partnership, Knightship, Lordship, Gloriuship, Leadership, Geniuship, Premiership, and Squireship, among others.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.